Gotham Asset Management LLC Trims Holdings in PerkinElmer, Inc. (PKI)

Gotham Asset Management LLC trimmed its position in shares of PerkinElmer, Inc. (NYSE:PKI) by 11.2% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 141,562 shares of the medical research company’s stock after selling 17,837 shares during the period. Gotham Asset Management LLC owned 0.13% of PerkinElmer worth $9,646,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Credit Suisse AG grew its holdings in PerkinElmer by 6.5% during the first quarter. Credit Suisse AG now owns 108,618 shares of the medical research company’s stock valued at $6,306,000 after purchasing an additional 6,665 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in PerkinElmer by 36.3% during the second quarter. Ontario Teachers Pension Plan Board now owns 95,415 shares of the medical research company’s stock valued at $6,502,000 after purchasing an additional 25,404 shares during the period. Morgan Stanley grew its holdings in PerkinElmer by 10.5% during the first quarter. Morgan Stanley now owns 272,720 shares of the medical research company’s stock valued at $15,834,000 after purchasing an additional 25,976 shares during the period. Neuberger Berman Group LLC grew its holdings in PerkinElmer by 59.8% during the second quarter. Neuberger Berman Group LLC now owns 52,030 shares of the medical research company’s stock valued at $3,545,000 after purchasing an additional 19,464 shares during the period. Finally, Legal & General Group Plc grew its holdings in PerkinElmer by 13.0% during the second quarter. Legal & General Group Plc now owns 100,010 shares of the medical research company’s stock valued at $6,815,000 after purchasing an additional 11,530 shares during the period. 91.47% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/09/gotham-asset-management-llc-trims-holdings-in-perkinelmer-inc-pki.html.

Shares of PerkinElmer, Inc. (NYSE:PKI) traded down 0.23% during midday trading on Monday, hitting $70.45. The company had a trading volume of 35,054 shares. The stock has a 50 day moving average price of $67.73 and a 200 day moving average price of $64.36. The firm has a market capitalization of $7.76 billion, a P/E ratio of 21.25 and a beta of 0.72. PerkinElmer, Inc. has a 1-year low of $45.35 and a 1-year high of $70.67.

PerkinElmer (NYSE:PKI) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. PerkinElmer’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS. On average, equities analysts anticipate that PerkinElmer, Inc. will post $2.89 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Investors of record on Friday, October 20th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Thursday, October 19th. PerkinElmer’s dividend payout ratio is currently 8.46%.

A number of research firms have recently commented on PKI. BidaskClub lowered PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price target for the company in a report on Wednesday, July 19th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $81.00 price target on shares of PerkinElmer in a report on Friday, August 4th. Citigroup Inc. raised their price target on PerkinElmer from $67.00 to $74.00 and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, Cantor Fitzgerald reaffirmed

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Credit Suisse AG grew its holdings in PerkinElmer by 6.5% during the first quarter. Credit Suisse AG now owns 108,618 shares of the medical research company’s stock valued at $6,306,000 after purchasing an additional 6,665 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in PerkinElmer by 36.3% during the second quarter. Ontario Teachers Pension Plan Board now owns 95,415 shares of the medical research company’s stock valued at $6,502,000 after purchasing an additional 25,404 shares during the period. Morgan Stanley grew its holdings in PerkinElmer by 10.5% during the first quarter. Morgan Stanley now owns 272,720 shares of the medical research company’s stock valued at $15,834,000 after purchasing an additional 25,976 shares during the period. Neuberger Berman Group LLC grew its holdings in PerkinElmer by 59.8% during the second quarter. Neuberger Berman Group LLC now owns 52,030 shares of the medical research company’s stock valued at $3,545,000 after purchasing an additional 19,464 shares during the period. Finally, Legal & General Group Plc grew its holdings in PerkinElmer by 13.0% during the second quarter. Legal & General Group Plc now owns 100,010 shares of the medical research company’s stock valued at $6,815,000 after purchasing an additional 11,530 shares during the period. 91.47% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This story was first posted by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are reading this story on another site, it was stolen and reposted in violation of United States and international trademark & copyright law. The original version of this story can be viewed at https://ledgergazette.com/2017/10/09/gotham-asset-management-llc-trims-holdings-in-perkinelmer-inc-pki.html.

Shares of PerkinElmer, Inc. (NYSE:PKI) traded down 0.23% during midday trading on Monday, hitting $70.45. The company had a trading volume of 35,054 shares. The stock has a 50 day moving average price of $67.73 and a 200 day moving average price of $64.36. The firm has a market capitalization of $7.76 billion, a P/E ratio of 21.25 and a beta of 0.72. PerkinElmer, Inc. has a 1-year low of $45.35 and a 1-year high of $70.67.

PerkinElmer (NYSE:PKI) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.67 earnings per share for the quarter, hitting the consensus estimate of $0.67. The company had revenue of $547.00 million during the quarter, compared to the consensus estimate of $554.14 million. PerkinElmer had a net margin of 16.80% and a return on equity of 13.44%. PerkinElmer’s quarterly revenue was up 2.0% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.67 EPS. On average, equities analysts anticipate that PerkinElmer, Inc. will post $2.89 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, November 10th. Investors of record on Friday, October 20th will be issued a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.40%. The ex-dividend date of this dividend is Thursday, October 19th. PerkinElmer’s dividend payout ratio is currently 8.46%.

A number of research firms have recently commented on PKI. BidaskClub lowered PerkinElmer from a “strong-buy” rating to a “buy” rating in a report on Wednesday, June 14th. Zacks Investment Research raised PerkinElmer from a “hold” rating to a “buy” rating and set a $78.00 price target for the company in a report on Wednesday, July 19th. Piper Jaffray Companies reaffirmed a “buy” rating and issued a $81.00 price target on shares of PerkinElmer in a report on Friday, August 4th. Citigroup Inc. raised their price target on PerkinElmer from $67.00 to $74.00 and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, Cantor Fitzgerald reaffirmed a “hold” rating on shares of PerkinElmer in a report on Sunday, July 16th. Two investment analysts have rated the stock with a sell rating, nine have issued a hold rating and five have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $67.77.

PerkinElmer Profile

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Want to see what other hedge funds are holding PKI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for PerkinElmer, Inc. (NYSE:PKI).

Institutional Ownership by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply